Lung cancer screening using an AI device for non-smokers with family history
A Prospective Study on Artificial Intelligence Guided Lung Cancer Screening for High-risk Never Smokers in Hong Kong
This study is testing if an AI tool can help screen for lung cancer in non-smokers aged 50 to 75 with a family history of the disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 3000 (estimated) |
| Ages | 50 Years to 75 Years |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT06295497 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the feasibility and clinical utility of an artificial intelligence-assisted program for lung cancer screening in Asian non-smokers aged 50 to 75 years who have a first-degree family history of lung cancer. A total of 1000 participants will undergo low-dose computed tomography (LDCT) scans, with the results interpreted by AI software to identify lung nodules. Those with detected nodules will receive further investigation. The study addresses the challenge of lung cancer screening in non-smokers, particularly in resource-limited settings in Asia.
Who should consider this trial
Good fit: Ideal candidates are non-smokers aged 50 to 75 with a first-degree family history of lung cancer.
Not a fit: Patients with a history of malignancy or significant medical comorbidities that prevent curative treatment will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier detection of lung cancer in high-risk non-smokers, potentially improving patient outcomes.
How similar studies have performed: While lung cancer screening in non-smokers is not widely established, emerging evidence suggests that AI-assisted screening could be a novel and promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients are eligible to be included in the study only if all of the following criteria apply: 1. Age 50-75 years old 2. Non-smoker (defined as less than 100 cigarettes in lifetime) 3. Having a first-degree family history of lung cancer 4. Physically fit for curative treatment if early-staged lung cancer is found 5. Able to provide written informed consent 6. Consent to follow up visits and follow up CT scan if indicated 7. Consent to blood taking for translational research Exclusion Criteria: Patients who meet any of the following exclusion criteria at screening are not eligible to be enrolled in this study: 1. History of malignancy 2. Smoking history (defined as more than 100 cigarettes in lifetime) 3. Clinical symptoms suspicious for lung cancer e.g. haemoptysis, chest pain, weight loss 4. Medical comorbidities that preclude curative treatment (surgery) for lung cancer, such as severe heart disease, acute or chronic respiratory failure, home oxygen therapy, bleeding disorder 5. Pregnant ladies or ladies planning for conception 6. History of tuberculosis or interstitial lung disease 7. Pneumonia requiring antibiotic treatment within the last 12 weeks 8. CT thorax or chest performed within 2 years (including LDCT, PET-CT, MRI thorax or suspicious of lung cancer) 9. Unable or unwilling to provide written informed consent
Where this trial is running
Hong Kong
- Department of Clinical Oncology, Prince of Wales Hospital — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Study coordinator: Molly SC LI, MBBS, MRCP
- Email: molly@clo.cuhk.edu.hk
- Phone: 3505 2166
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.